Praxis Precision Medicines, INC 10-Q quarterly reports

Praxis Precision Medicines, Inc. (PRAX) filed its Q2 2026 10-Q, detailing strong cash position, progress on multiple drug candidates, and a setback in the vormatrigine program.

Praxis Precision Medicines reports increased R&D spending and net loss in Q1 2026, but maintains a strong cash position and advances multiple drug candidates.

Praxis Precision Medicines reports significant clinical progress across its CNS pipeline, including positive Phase 3 results for ulixacaltamide and Breakthrough Therapy Designation for relutrigine, while extending its cash runway into 2028 with a recent $567 million public offering.

Praxis Precision Medicines reported a significant increase in net loss for Q2 2025 driven by expanded R&D, while extending its cash runway into 2028 and advancing multiple clinical programs.

Praxis Precision Medicines reports a net loss of $69.3 million for Q1 2025, focusing on advancing clinical trials and research efforts.

Praxis Precision Medicines reports a net loss of $51.9 million for the third quarter of 2024, while advancing its clinical programs and maintaining a strong cash position.

Praxis Precision Medicines reports a net loss of $72.2 million for the first half of 2024, while advancing its clinical programs and securing significant funding.

Praxis Precision Medicines reported a net loss of $39.6 million for the first quarter of 2024, while highlighting progress in its clinical programs and a strengthened financial position.